Free Trial
ASX:GTG

Genetic Technologies (GTG) Stock Price, News & Analysis

Genetic Technologies logo

About Genetic Technologies Stock (ASX:GTG)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
$9.45 million
P/E Ratio
N/A
Dividend Yield
8.62%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Receive GTG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

GTG Stock News Headlines

Genetic Technologies Enters Voluntary Administration
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
Genetic Technologies Extends Securities Offer Deadline
Genetic Technologies Extends Entitlement Offer Deadline
Genetic Technologies Extends Offer and Suspends Trading
See More Headlines

GTG Stock Analysis - Frequently Asked Questions

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
Current Symbol
ASX:GTG
CIK
N/A
Fax
N/A
Employees
60
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.02 million
Net Margins
-137.21%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$9.67 million
Price / Cash Flow
N/A
Book Value
A$0.01 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$9.45 million
Optionable
Not Optionable
Beta
0.50
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (ASX:GTG) was last updated on 6/6/2025 by MarketBeat.com Staff
From Our Partners